Phase II Study of Irinotecan Plus Cisplatin as First Line therapy in Extensive Small-Cell Lung Cancer |
Hwang, Ki Eun
(Department of Internal Medicine, College of Medicine, Wonkwang University)
Kim, So Young (Department of Internal Medicine, College of Medicine, Wonkwang University) Jung, Jong Hoon (Department of Internal Medicine, College of Medicine, Wonkwang University) Park, Seong Hoon (Department of Radiology, College of Medicine, Wonkwang University) Park, Jung Hyun (Department of Internal Medicine, College of Medicine, Wonkwang University) Kim, Hwi Jung (Department of Internal Medicine, College of Medicine, Wonkwang University) Kim, Hak Ryul (Department of Internal Medicine, College of Medicine, Wonkwang University) Yang, Sei Hoon (Department of Internal Medicine, College of Medicine, Wonkwang University) Jeong, Eun Taik (Department of Internal Medicine, College of Medicine, Wonkwang University) |
1 | Jeong ET. Clinical survey of lung cancer in Korea. Tuberc Respir Dis 2000;49:137-48 DOI |
2 | Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, et al. Antitumor activity of 7-ethyl- 10-(4-(1-piperidino)-1-piperidino)carbonyloxy-camptoth ecin, a novel water-soluble derivative of camptothecin against murine tumors. Cancer Res 1987;47:5944-7 |
3 | Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, et al. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10:1225-9 DOI |
4 | Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-91 DOI |
5 | Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8 |
6 | Jeong HL, Lee SY, Kim JH, Ha ES, Jung JY, Lee KJ, et al. Phase II trial of irinotecan plus cisplatin combinations on first line therapy for patients with small cell lung cancer. Tuberc Respir Dis 2005; 60:57-64 DOI ScienceOn |
7 | WHO handbook for reporting the results of cancer treatment. No. 48. Geneva: World Health Organization, 1979 |
8 | Witta SE, Kelly K. Chapter 46, chemotherapy for small cell lung cancer ln;Pass HI, Carbone DP, Johnson DH, Minna JD, Turris AT, editors, Lung cancer, 3rd ed. Philadephia: Lippincott Williams and Wilkins:2005. p657-73 |
9 | Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-43 DOI ScienceOn |
10 | Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients With non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006;24:2237-44 DOI ScienceOn |
11 | Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-809 DOI |
12 | Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small -cell lung cancer. J Natl Cancer Inst 1991;83:1164-8 DOI |
13 | Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998;95:8170-4 |
14 | Font A, Taron M, Rosell R. UGT1A1 genotyping correlates with toxicity and survival in non-small cell lung cancer (NSCLC) patients treated with secondline CPT-11/docetaxel. Proc Am Soc Clin Oncol 2001;20:340a |
15 | Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 1998; 16:1068-74 DOI |
16 | Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91 DOI ScienceOn |
17 | Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, et al. Prospective randomized comparison of high dose and standard dose etoposide and cisplatin chemotherapy on patients with extensive stage small cell lung cancer. J Clin Oncol 1994; 12:2022-34 DOI |